
Gates Foundation Unveils US$2.5 Billion Initiative for Women-Led Research and Solutions
The Gates Foundation announced a US$2.5 billion commitment through 2030 to accelerate research and development (R&D) focused exclusively on women's health.
It will support the advancement of more than 40 innovations in five critical, chronically underfunded areas—particularly those affecting women in low- and middle-income countries.
"For too long, women have suffered from health conditions that are misunderstood, misdiagnosed, or ignored," said Dr. Anita Zaidi, President, Gates Foundation's Gender Equality Division. "We want this investment to spark a new era of women-centered innovation—one where women's lives, bodies, and voices are prioritized in health R&D."
"Investing in women's health has a lasting impact across generations. It leads to healthier families, stronger economies, and a more just world," said Bill Gates, Chair, Gates Foundation. "Yet women's health continues to be ignored, underfunded, and sidelined. Too many women still die from preventable causes or live in poor health. That must change. But we can't do it alone."
To close persistent gaps in funding and research, the foundation is urging governments, philanthropists, investors, and the private sector to co-invest in women's health innovations, help shape product development, and ensure access to treatments for the women and girls who need them most.
"This is the largest investment we've ever made in women's health research and development, but it still falls far short of what is needed in a neglected and underfunded area of huge human need and opportunity," said Zaidi. "Women's health is not just a philanthropic cause—it's an investable opportunity with immense potential for scientific breakthroughs that could help millions of women. What's needed is the will to pursue and follow through."
The foundation's investment will advance innovation across five high-impact areas of a woman's lifespan:
Obstetric care and maternal immunization: Making pregnancy and delivery safer
Maternal health and nutrition: Supporting healthier pregnancies and newborns
Gynecological and menstrual health: Advancing tools and research to better diagnose, treat, and improve gynecological health and reduce infection risk
Contraceptive innovation: Offering more accessible, acceptable, and effective options
Sexually transmitted infections (STIs): Improving diagnosis and treatment to reduce disproportionate burdens on women
The five priority areas were selected based on a combination of data and evidence about where innovation can save and improve the most lives, direct insights from women in low- and middle-income countries about their needs and preferences, and the persistently high rates of misdiagnosis caused by gaps in medical knowledge and training. They also reflect the unique challenges faced in low-resource settings, making these areas especially ripe for broader public and private investment to drive meaningful, scalable impact.
This work supports the foundation's long-term goals through 2045: helping to end preventable deaths of moms and babies; ensuring the next generation grows up without having to suffer from deadly infectious diseases; and lifting millions of people out of poverty, putting them on a path to prosperity. It builds on a 25-year legacy of advancing maternal and child health and supporting women's empowerment globally. The R&D commitment complements the foundation's work supporting the scale-up and delivery of women's health commodities, vaccines such as the HPV vaccine, and child health.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Denmark Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, H. Lundbeck, Leo, Orifarm, ALK-Abell, Xellia, Takeda, Sandoz, Ferring Pharmaceuticals, FUJIFILM
Denmark's pharmaceutical market is projected to grow from US$ 3.81 billion in 2024 to US$ 5.20 billion by 2033, with a CAGR of 3.52%. Key drivers include advanced health data infrastructure, supportive government policies, heavy R&D investment, and contributions from pharmaceutical giants like Novo Nordisk and Lundbeck. The aging population, rise in chronic diseases, and demand for innovative treatments further fuel growth. However, challenges such as regulatory complexity and sustainability pressures persist. The market encompasses a wide range of therapeutic classes and distribution channels, making Denmark a competitive hub for pharmaceutical R&D and innovation. Danish Pharmaceutical Market Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Denmark Pharmaceutical Market - Drug Development & Forecast 2025-2033" report has been added to Pharmaceutical Market is expected to reach US$ 5.20 billion by 2033 from US$ 3.81 billion in 2024, with a CAGR of 3.52% from 2025 to 2033 Heavy R&D spending, government assistance, well-developed healthcare system, aging population, growth in the incidence of chronic diseases, advances in biotechnology, world demand for exports, and the location of world-class pharmaceutical giants such as Novo Nordisk and Lundbeck are all determinants of Denmark's expanding pharmaceutical market. Investigation, research, production, and promotion of drugs and therapies utilized to cure, prevent, or control disease fall within the pharmaceutical sector. Through the provision of innovative medical treatments and increased life expectancy and quality of life, it plays an important role in world medicine. Scientific breakthroughs, government approvals, and the ongoing demand for effective treatments drive this industry. Both small biotech firms and international corporations are prominent players. Prescription drugs, vaccines, and over-the-counter drugs are all pharmaceuticals. The sector often collaborates with research and clinical institutions to accelerate development and is highly regulated to ensure safety and efficacy of R&D expenditures, a collaborative academic and health environment, and supportive government regulations are the primary impetus for Denmark's pharmaceutical industry. Major contributions are made by leading global companies such as Novo Nordisk and Lundbeck through specialty medicine creation and global exports. Demand within the domestic market is also boosted by an aging population and the spread of chronic diseases such as diabetes. Innovation through personalized therapy and real-world evidence creation are enabled by advanced health data infrastructure in Denmark. Its global competitiveness is enhanced by an open regulatory system and access to EU markets. These combine to offer a robust, future-proof pharmaceutical sector with scope to Drivers for the Denmark Pharmaceutical Market Advanced Health Data InfrastructureOne of the key drivers for Denmark's pharmaceutical market's growth is its advanced heath data infrastructure. With biobanks, illness registries, and population-level electronic health records, the country boasts one of the most advanced and unified systems of healthcare data in the world. Since every Danish citizen is assigned a personal identification number, medical records can be exactly correlated between clinics, hospitals, and pharmacies. The approach opens up real-world data to academics and pharma companies to facilitate post-marketing surveillance, drug development, and clinical trials. Such access reduces the cost and time-to-market of research as well as speeds up pharmacovigilance and personalized treatment innovation. It also enhances the quality and efficiency of clinical trials by enabling long-term follow-up and targeted patient recruitment. In addition, Denmark is a safe destination for international collaboration due to the stringent data protection legislation that ensures patient confidentiality. This technological advantage enhances Denmark's competitiveness in the life sciences world and makes it a leading site for pharmaceutical R& Government PoliciesDenmark's pharma industry is growing largely due to the favorable government policies of the country. Denmark has established a comprehensive Life Sciences Growth Plan incorporating 36 initiatives across six key areas such as clinical trials, R&D, and regulatory environments. This strategic plan aims to further consolidate Denmark's reputation as a leading life sciences nation by fostering innovation and streamlining establishment of a "one-stop-shop" for drug companies that simplifies and quickens the regulatory approval process is an essential component of this program. By reducing administrative barriers, this program makes it easier for businesses to set up and expand production sites in Denmark. In addition, Denmark's climate agreement with the pharmaceutical industry illustrates its commitment to environmental responsibility. Consistent with international environmental aims, our partnership works to support green innovation and reduce CO2 emissions. Overall, taken as a package, all these beneficial government programs offer a good environment for pharmaceutical companies to expand, innovate, and become globally competitive for Denmark's pharmaceutical R&D InvestmentHigh investment in research and development (R&D) is one of the factors propelling the growth of the pharmaceutical market in Denmark. With a significant proportion being allocated to life sciences and pharmaceuticals, the country has some of the highest R&D expenditures per GDP of any nation globally. Both the public funding of the Danish government and substantial contributions from the private sector - particularly from major players such as Novo Nordisk and Lundbeck - funding this hospitals, and enterprise are in close collaboration to facilitate Denmark's R&D environment that encourages innovation in biotechnology, personalized medicine, and drug development. Tax reductions, subsidies, and strategic initiatives such as the Life Sciences Growth Plan are some of the government measures that actively encourage R&D. Contemporary research infrastructure and highly skilled staff are also available, which adds to Denmark's competitive edge. This robust R&D climate accelerates the development of novel treatments, attracts foreign partnerships, and makes Denmark a world leader in clinical excellence and pharmaceutical in the Denmark Pharmaceutical Market Regulatory Complexity and EU ComplianceEU compliance and regulatory complexity provide major obstacles for Denmark's pharmaceutical industry. Businesses have to deal with two sets of regulations: strict European Union guidelines and Danish state laws. This results in a complicated and frequently drawn-out approval process for new medications and clinical studies, which can raise expenses and postpone market entry. Startups and small and medium-sized businesses (SMEs) frequently find it difficult to satisfy these standards due to the resource requirements and administrative load. Furthermore, ongoing adaptation is necessary due to the EU's periodic revisions and harmonization initiatives. For Danish pharmaceutical businesses, sustaining innovation speed while balancing compliance is still a major and Green TransitionFor Denmark's pharmaceutical industry, sustainability and the green transition pose increasing obstacles. There is growing pressure on the business to lessen its environmental impact, which includes controlling water use in manufacturing processes, cutting carbon emissions, and limiting waste. Significant investments in cleaner technologies and process innovations are necessary to meet Denmark's aggressive climate targets and EU environmental requirements. Pharmaceutical businesses also need to strike a balance between sustainability measures and preserving cost-effectiveness and production efficiency. Changes in sourcing procedures and supply networks are also necessary for this shift. The Danish pharmaceutical industry must overcome the difficult task of successfully incorporating green practices while maintaining its competitiveness in order to keep up with worldwide sustainability trends. Key Players Analysis: Company Overview, Key Persons, Recent Development & Strategies, SWOT Analysis, Sales Analysis Novo Nordisk A/S H. Lundbeck A/S Leo Pharma A/S Orifarm Group A/S ALK-Abell A/S Xellia ApS Takeda Pharma A/S Sandoz A/S Ferring Pharmaceuticals A/S FUJIFILM Diosynth Biotechnologies Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $3.81 Billion Forecasted Market Value (USD) by 2033 $5.2 Billion Compound Annual Growth Rate 3.5% Regions Covered Denmark Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Denmark Pharmaceutical Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Therapeutic Class6.2 By Drug Type6.3 By Prescription Type6.4 By Distribution Channel7. Therapeutic Class7.1 Cancer7.1.1 Market Analysis7.1.2 Market Size & Forecast7.2 Infectious Diseases7.3 Cardiovascular Diseases7.4 Diabetes7.5 Respiratory Diseases7.6 Central Nervous System Disorders7.7 Autoimmune Diseases7.8 Others8. Drug Type8.1 Branded8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Generic9. Prescription Type9.1 OTC Drugs9.1.1 Market Analysis9.1.2 Market Size & Forecast9.2 Prescription Drugs10. Distribution Channel10.1 Hospital Pharmacy10.1.1 Market Analysis10.1.2 Market Size & Forecast10.2 Retail Pharmacy10.3 Others11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Novo Nordisk A/S14.2 H. Lundbeck A/S14.3 Leo Pharma A/S14.4 Orifarm Group A/S14.5 ALK-Abell A/S14.6 Xellia ApS14.7 Takeda Pharma A/S14.8 Sandoz A/S14.9 Ferring Pharmaceuticals A/S14.10 FUJIFILM Diosynth Biotechnologies15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Danish Pharmaceutical Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 hours ago
- Yahoo
IVI RMA North America 2025 Innovation Summit to Shape the Future of Fertility Care
September Virtual Event will Connect Fertility Experts with Innovative Technologies BASKING RIDGE, N.J., August 05, 2025--(BUSINESS WIRE)--IVI RMA North America, a world-class leader in reproductive medicine and fertility care, is proud to announce its 2025 Innovation Summit—an immersive virtual event designed to foster strategic partnerships and spotlight emerging technologies that will shape the future of reproductive healthcare. Taking place on September 10 and 11, 2025, the IVI RMA Innovation Summit is a unique opportunity for selected companies and creators to present directly to IVI RMA's executive leadership and key stakeholders from clinical, lab, and administrative teams. Each organization will receive a dedicated 30-minute presentation slot followed by a live 15-minute question-and-answer session—designed to foster real-time dialogue and meaningful connections. IVI RMA North America invites forward-thinking startups, research teams, technology leaders, and existing collaborators to be part of this exciting initiative. Whether focused on enhancing patient experience, streamlining clinical operations, or improving fertility treatment outcomes, this event provides a valuable opportunity to contribute to the next chapter of innovation in reproductive medicine. "IVI RMA North America is committed to pushing the boundaries of what's possible, and this event demonstrated that commitment, serving not only as a platform for introducing groundbreaking solutions but also as a space to celebrate what IVI RMA has accomplished in partnership with other industry pioneers," said Lynn Mason, CEO of IVI RMA North America. "The Innovation Summit offers our partners the opportunity to highlight new initiatives, while welcoming new prospective collaborators whose missions align with IVI RMA's patient-centered, science-driven approach to care." As part of IVI RMA Global, the largest assisted reproduction group in the world, IVI RMA North America is backed by more than 4,400 professionals across 190+ locations in 14 countries. To learn more and apply to present at the 2025 IVI RMA Innovation Summit, please visit: About IVI RMA North America IVI RMA North America, comprising Reproductive Medicine Associates, Boston IVF, and Toronto-based TRIO, spans 22 IVF laboratories and has helped women achieve pregnancies which have led to the birth of over 220,000 babies to date. Pioneers in innovative care, including PGT-A, single embryo transfer, fertility preservation, LGBTQ+ care, and more, the network has published over 1,000 papers which have pushed the fertility industry forward. Part of IVI RMA Global, one of the world's leading Reproductive Medicine groups committed to providing evidence-based fertility solutions with the greatest chance of success in the shortest time necessary to patients seeking treatment anywhere in the world. IVI RMA Global employs more than 4,500 people across 200+ locations in 15 countries. Learn more at and View source version on Contacts IVI RMA North America Contact Andy Swan, Vice President, Strategic Partnershipsaswan@
Yahoo
5 hours ago
- Yahoo
Zero Candida Technologies to Present at the OTCQB Venture Virtual Investor Conference on August 7th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a medical device company developing a SMART, AI-driven FemTech device to revolutionize women's health, today announced that Sophya Galper Komet, CFO, and Dr. Asher Holzer, Founder, will present live at the OTCQB Venture Virtual Investor Conference hosted by on August 7th , 2025. DATE: August 7th TIME: 12:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: August 7 & 8, 2025 This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Company Highlights Demonstrated 99.999% Candida elimination in 3 hours during POC testing, targeting FDA De Novo regulatory pathway Expanding global IP portfolio with patents filed in Europe, the United States, Brazil, and fully granted in South Africa Cross-listed on FSE and OTCQB, including recent DTC eligibility, broadening investor access In active discussions with major hospitals and U.S. pharmaceutical companies to support future clinical trials and commercialization About Zero Candida Technologies Zero Candida Technologies, Inc. is a publicly traded FemTech company pioneering innovative solutions to address unmet needs in women's health. The Company is developing a SMART, tampon-like device that combines artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat Vulvo-Vaginal Candidiasis (VVC) through personalized, at-home care. This condition affects approximately 75% of women worldwide, and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed. With the VVC treatment market projected to exceed US $2B by 2030, Zero Candida is combining hybrid medicine and technology-based diagnostics to improve access for underserved populations and bring gynecology into the 21st century. To learn more, visit About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Zero Candida Technologies, Inc.+1 (647) 874-3767 investors@ Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@